[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sandwell & West Birmingham Hospitals NHS Trust\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":117},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,70,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100576864","correlation-of-ffr-ct-with-invasive-ffr-in-multi-ethnic-cohort--a-retrospective-study-100576864",false,"NCT06790836","Correlation of FFR CT With Invasive FFR in Multi-ethnic Cohort- a Retrospective Study","Correlation of Fractional Flow Reserve Computed Tomography (FFR CT) Findings With Invasive FFR in Coronary Artery Disease (CAD) in a Multi-ethnic Cohort- a Retrospective Study","Inclusion Criteria:\n\n* •≥18 years\n\n  * Stable •patients with suspected CAD\n  * Patients who underwent CTCA, FFR CT and had an invasive FFR.\n  * CTCA images of high-quality for analysis, with clear visualisation of coronary arteries and minimal artifacts.\n\nExclusion Criteria:\n\n* •\\\u003C18 years of age\n\n  * Did not undergo FFR CT\n  * Inadequate quality\u002Fdegraded CTCA images","ALL","18 Years",{"count":19,"type":20},500,"ESTIMATED","OBSERVATIONAL","This study aims to examine the correlation between Fractional Flow Reserve (FFR) FFR Computed Tomography (CT) and invasive FFR in a real-world setting using retrospective analysis of existing data, providing practical insights directly applicable to patient care. By confirming or examining the accuracy of FFR CT in a clinical setting, our analysis could support its broader adoption as a routine non-invasive diagnostic tool potentially (a) reducing the need for invasive testing (b) minimising associated risks, and(c) lowering healthcare costs and provide fresh insights into non-invasive coronary diagnostics. Our findings will also help understand the relevance of these tests across different ethnic groups and the population we serve.",[24],"Coronary Artery Disease",[26,27,28],"FFR CT","Invasive FFR","Comparison","RECRUITING","2026-05-01",{"date":32,"type":33},"2026-05-07","ACTUAL",{"date":30,"type":20},{"date":36,"type":20},"2026-12-01",{"name":38,"class":39},"Sandwell & West Birmingham Hospitals NHS Trust","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100574938","cardiovascular-screening-in-asymptomatic-south-asians-100574938","NCT06765785","Cardiovascular Screening in Asymptomatic South Asians","Cardiovascular Screening in Asymptomatic South Asians - a Pilot Randomized Comparison of Q-risk 3 Score Versus Computed Tomography Coronary Angiography (CTCA)","Inclusion Criteria:\n\n* Asymptomatic South Asian patients of age\n\n  * men≥30 years ≤60 years\n  * Women \\>50 years ≤60 years\n\nPlus at least one of the following risk factors:\n\n* hypertension (HTN)\n* diabetes mellitus (DM)\n* hyperlipidaemia\n* family history of premature coronary artery disease (male \\\u003C45 years, female \\\u003C55 years)\n* smoking (current or ex-smoker in the last 3 months)\n\nExclusion Criteria:\n\n* Patients meeting any of the following criteria will be excluded\n\n  * Patients unable to give written informed consent\n  * History of previous coronary events\u002FCABG\u002F coronary stenting or CTCA in the last 4 years\n  * Patients with pre-existing cardiac symptoms\n  * Patients who could or are pregnant\n  * Allergy to iodine contrast\n  * Active ongoing malignancy and treatment for the same\n  * eGFR ≤30ml\u002Fmin\u002F1.72m2\n  * Participation in any other interventional research trial","30 Years","60 Years",{"count":51,"type":20},50,"INTERVENTIONAL",[54],"NA","Cardiovascular disease (CVD) is the leading cause of morbidity, mortality and healthcare costs in the United Kingdom. Ethnic minorities like South Asians (SA) have a 3-5 times higher incidence of CVD as predicted by various risk scores despite similar or fewer traditional cardiovascular risk factors.\n\nComputed Tomography Coronary Angiography (CTCA) is able to outline the coronary anatomy determining the site, severity and type of atherosclerotic plaque location in the heart arteries. The National Institute for Health and Care Excellence (NICE) guidelines recommends CTCA as the first line investigation for stable chest pain considered to be coming from the heart (angina).\n\nHowever there is no pathway for the patients who are asymptomatic but at high risk of CVD, such as the SA cohort. Current practice involves using risk scores to guide management of asymptomatic adults. One recommended and commonly used score is the Q-risk score (the QRISK ® 3-2018 risk calculatorhttps:\u002F\u002Fqrisk.org \\> three). This score incorporates ethnicity amongst other risk factors and patients with a risk ≥10% of having a heart attack or stroke in the next 10 years are offered primary prevention treatment with low dose statin therapy. For example, an average (height 164cm weight 70kg) 40 year old male of SA descent, without symptoms who is a non-smoker but with Diabetes Mellitus (DM) on tablet treatment scores 5.8% - this risk is not high enough to warrant treatment with a statin unless he also has abnormally raised cholesterol levels. But this patient is still high risk of CVD due to his ethnicity and DM. There is no current evidence to tailor treatment in such asymptomatic, high risk ethnic minorities.\n\nSimilar to screening programs for cancer, screening CTCA, compared to risk stratification with the QRISK ® 3 score, may help in risk stratification of a higher proportion of SA patients. 50 asymptomatic SA patients from 2 sites (25 patients each site) with one CV risk factor will be randomised to either Q-risk 3 score or to screening CTCA.",[57,58,59],"Cardiovascular Diseases","Asymptomatic Condition","South Asian",[59],"NOT_YET_RECRUITING","2025-01-08",{"date":64,"type":33},"2025-01-10",{"date":66,"type":20},"2024-12-31",{"date":68,"type":20},"2027-07-31",{"name":38,"class":39},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":79,"conditions":80,"keywords":84,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":40},"100547944","calcification-on-ctca-of-a-cto-and-pci-outcomes-100547944","NCT06414551","Calcification on CTCA of a CTO and PCI Outcomes","Characteristics of Calcification in a Chronic Total Occlusion on Computed Tomography Coronary Angiogram and Percutaneous Coronary Intervention Outcomes- a Single Centre Observational Study","Inclusion Criteria:\n\n* Patients meeting all the below criteria will be included\n\n  * ≥18 years\n  * Previous CTO PCI attempt in the last 5 years\n  * Undergone CTCA either pre or post CTO PCI\n  * Adequate CTCA images for analysis\n\nExclusion Criteria:\n\n* Patients meeting any of the following criteria will be excluded\n\n  * \\\u003C18 years of age\n  * Did not undergo CTCA\n  * Inadequate\u002Fdegraded CTCA images",{"count":78,"type":20},100,"A chronic total occlusion (CTO) is present in 15-20% of patients who are referred for invasive coronary angiography. CTO Percutaneous Coronary Intervention (PCI) procedure success rates have increased over the years and can be as high as 90% when performed by high-volume CTO operators.Procedurally, excess calcification in the CTO anatomy is one factor which makes it difficult to complete the procedure or obtain ideal stent expansion. Excess calcification is best identified by Computed Tomography Coronary Angiography (CTCA) rather than invasive angiography.\n\nThe investigators plan to retrospectively evaluate CTCA in patients who underwent CTO PCI and correlate calcification characteristics with CTO PCI outcomes and tools utilised for calcium modification.",[81,82,83],"Chronic Total Occlusion of Coronary Artery","Calcification","Computed Tomography Angiography",[85,86],"CTCA","CTO","2024-08-28",{"date":89,"type":33},"2024-08-30",{"date":91,"type":33},"2024-07-19",{"date":93,"type":20},"2025-07-01",{"name":38,"class":39},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":52,"phases":105,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":40},"100444586","whole-body-photobiomodulation-and-chronic-pain-trial-100444586","NCT05069363","Whole-Body Photobiomodulation and Chronic Pain Trial","Whole-Body Photobiomodulation Therapy for Chronic Pain: a Feasibility Trial","Inclusion Criteria:\n\nPatients eligible for the trial must comply with all of the following:\n\n1. Currently diagnosed or receiving treatment for a widespread chronic pain condition, including but not limited to:\n\n   1. Axial pain of any origin\n   2. Polyathralgia of any origin\n   3. Myofascial pain of any origin\n   4. A diagnosis of chronic widespread pain or FM\n2. Able to provide informed written consent\n3. ≥18 years\n4. Able to commit time to the trial treatment schedule of 6 weeks\n5. Score as low or moderate risk on the COVID-19 risk stratification tool - applicable for the duration of the pandemic\n\nExclusion Criteria:\n\n1. Pregnancy\n2. Severe skin diseases (e.g. skin cancer, severe eczema, dermatitis, or psoriasis)\n3. Body weight ≥136kg, as per manufacturer instructions \\[see Appendix 3\\]\n4. Uncontrolled co-morbidities (e.g. uncontrolled diabetes defined as HbA1c \\>69mmol\u002Fmol, decompensated heart failure, major psychiatric disturbance such as acute psychosis or suicidal ideation)\n5. Use of systemic corticosteroid therapy including oral prednisolone or corticosteroid injections within the preceding 6 months as recommended by the manufacturer; steroids are thought to inhibit the anti-inflammatory effect of photobiomodulation therapy\n6. Known active malignancy\n7. Inability to enter the NovoTHOR device or lie flat for 20 minutes (either due to physical reasons or other e.g. claustrophobia)\n8. Patients speaking a language for which an interpreter cannot be sought","100 Years",{"count":104,"type":20},20,[54],"Chronic pain is a common long-term condition that can affect any area throughout the body. Individuals suffering with chronic pain often have associated fatigue, sleep and mood disturbances.\n\nCurrent treatments for chronic pain include a variety of both medicine-based approaches and non-medical approaches such as exercise and psychology treatments. Patients often take a combination of medications such as antidepressants and strong medications like morphine - which are not always effective, and often associated with several troublesome side effects. Despite physical activity being a common and helpful treatment, evidence shows that patients with chronic pain can find it difficult to engage for a variety of reasons. It would be helpful to see if other non-medication based approaches will be an acceptable treatment to those suffering with chronic pain.\n\nPhotobiomodulation (PBM) therapy describes a safe, non-invasive low-energy light therapy that has been successful in treating a variety of chronic pain conditions. Cells absorb light to produce a series of reactions that culminate in pain relief, reduced inflammation, and tissue repair. Most studies examining effects of PBM have consisted of a small hand-held probe focused on specific painful areas. There are a cohort of chronic pain conditions that encompass widespread throughout the back, neck and joints, such as fibromyalgia (FM). Whole-body PBM therapy is able to treat a large area of the body in a short space of time.\n\nThe main purpose of the study is to determine feasibility, with a view to guiding a definitive Randomised Controlled Trial (RCT), in terms of: feasibility of eligibility criteria, recruitment rates, acceptability of trial device in the chronic pain population, and acceptability of outcome measures.",[108],"Chronic Pain","2022-06-26",{"date":111,"type":33},"2022-06-30",{"date":113,"type":33},"2022-01-12",{"date":115,"type":20},"2023-09",{"name":38,"class":39},""]